Omeros (OMER) Raised to Strong-Buy at ValuEngine

Omeros (NASDAQ:OMER) was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a report released on Wednesday, April 3rd, ValuEngine reports.

A number of other equities research analysts have also issued reports on OMER. Maxim Group set a $32.00 price objective on shares of Omeros and gave the company a “buy” rating in a report on Thursday, December 6th. Zacks Investment Research lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Omeros in a report on Tuesday, December 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $27.00.

NASDAQ:OMER traded up $0.03 during trading hours on Wednesday, reaching $18.81. 214,270 shares of the company were exchanged, compared to its average volume of 613,702. The stock has a market capitalization of $920.45 million, a PE ratio of -8.47 and a beta of 3.60. Omeros has a twelve month low of $10.30 and a twelve month high of $27.00.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Friday, March 1st. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.37. The company had revenue of $22.02 million for the quarter, compared to analyst estimates of $22.42 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share. The business’s revenue was up 60.0% on a year-over-year basis. Equities research analysts predict that Omeros will post -0.3 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its stake in Omeros by 0.8% during the fourth quarter. BlackRock Inc. now owns 3,989,206 shares of the biopharmaceutical company’s stock worth $44,439,000 after buying an additional 31,270 shares during the period. Vanguard Group Inc lifted its position in shares of Omeros by 1.6% during the third quarter. Vanguard Group Inc now owns 2,204,427 shares of the biopharmaceutical company’s stock worth $53,810,000 after purchasing an additional 34,043 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Omeros by 1.6% during the third quarter. Vanguard Group Inc. now owns 2,204,427 shares of the biopharmaceutical company’s stock worth $53,810,000 after purchasing an additional 34,043 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of Omeros by 49.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,912,244 shares of the biopharmaceutical company’s stock worth $21,303,000 after purchasing an additional 632,840 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Omeros by 844.8% during the fourth quarter. Millennium Management LLC now owns 1,112,584 shares of the biopharmaceutical company’s stock worth $12,394,000 after purchasing an additional 994,829 shares in the last quarter. 49.07% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: Beige Book

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.